To study AR’s roles in RCC progression, we first targeted AR by adding either AR-shRNA in VHL-mutant SW-839 and OSRC-2 cells, or functional AR-cDNA in OSRC-2 and VHL-wild-type Caki-1 cells (Fig. 1a). Here, VHL is linked to renal cell carcinoma.